Panakeia
Panakeia is looking to improve patient outcomes by making biomarker profiling faster and more accessible.
Today, cancer diagnosis relies on pathologist assessment of biopsy images. Full cancer diagnosis requires at least 4 tests conducted in separate laboratories. This takes an average of 20 days, and costs hospitals several thousand pounds.
Panakeia aims at providing comprehensive ‘omics’ molecular analysis of patient tissues, which is faster and cheaper than other methods. Their AI-powered technologies will provide biomarker information directly from H&E-stained tissue images, offering reliable results in minutes. The new process will fit within clinicians’ existing workflows, and patients will be able to receive a diagnosis from one single test, in only two days, and at a fraction of the cost.
Founders
Pahini Pandya
CEO
Pahini holds a PhD from King’s College London in Cell and Molecular Biophysics. Her research took her into the failure of protease inhibitors as potential therapeutic agents for cancer. Prior to cofounding Panakeia, Pahini was a Research Associate at Cambridge University. She is also currently part of the Global Shapers Community (an initiative of the World Economic Forum), a network of Hubs developed and led by young people who are exceptional in their potential, achievements, and drive to make a contribution to their communities.
Pandu Raharja
CTO
Pandu has eight years of award winning expertise in machine learning, computational biology, mathematical modelling as well as cancer drug discovery and design. He managed research projects and products within major organisations (including Siemens, Roche, Vodafone) as well as publications of state-of-the-art methods in biomedical image analysis and genomics. Pandu holds degrees in Bioinformatics, Computer Science and Mathematics from ETH Zurich, LMU Munich, the Technical University of Munich, and Cambridge University.
Milestones
Founded at Entrepreneur First
Seed (2.8 million) led by Hoxton Ventures